KorePartner Spotlight: Scott Pantel, President & CEO of Life Science Intelligence

by | Friday February 4, 2022
KorePartner Spotlight: Scott Pantel, President & CEO of Life Science Intelligence

With the launch of the KoreConX all-in-one platform, KoreConX is happy to feature the partners contributing to its ecosystem. 

 

During the capital raising journey, many things must be in place to increase the potential for success. One of these critical factors is having the right team to assist with gaining information on your demographic is vital to a successful capital raise.

 

As the President and CEO of LSI, Scott Pantel knows the importance of this, which is why Life Science Intelligence was formed. Scott knows that the most important and strategic business decisions must be made based on data and insights from trusted advisors. LSI is proud to be the go-to-market research firm to support those making these big decisions because of their experience in the Medtech field. With a team of economists, analysts, and market researchers, LSI provides deep knowledge of the healthcare industry, guiding clients with actionable data to identify significant trends in medical devices, diagnostic, and digital health technologies that are rapidly evolving in the industry.

 

We took some time to speak with Scott to learn more about him, his company, and his thoughts on the future of market research, advisory, and raising capital.

 

Q: What does your company do, and how are you making a difference?

A: We’re a Medtech-focused market research and advisory company. We help early-stage companies all the way up to the largest healthcare companies in the world, and their investors, make the best strategic decisions possible. We do this through independent research, consulting, advisory and partnering events.

 

Q: What excites you about the Medtech, Life Sciences, and Biotech Industries?

A: The thing that excites me most about Medtech is that we get to have an impact on people’s lives. The innovators in our space save lives and reduce suffering. To borrow a quote from our 2020 Keynote Speaker and Co-Founder of Auris Health (acquired by J&J for $5.8B), “Medtech is the best and original impact investment sector.”  The innovators in our sector are literally changing and saving lives.  I also get excited to see that patients are increasingly becoming more involved in their healthcare decisions. The convergence of medical devices, data, and smart technologies improves patient outcomes and is slowly but surely making our healthcare system more efficient. We have a long way to go, but I believe we are on the right track, and we will see some quantum leaps in medical technology over the coming years.  

 

Q: How do you see the LSI Medtech event impacting your company and industry?

A: This event connects the innovators with the capital sources they need to commercialize life-changing and saving technologies.  Innovations need capital and strategic partners to scale and get to the market.  Our event connects all of the stakeholders in the Medtech ecosystem so that good things can happen and we can get technologies to market faster.

 

Q: Why do you think education on RegA+ plays such a vital role in expanding access to capital for Medtech companies?

A: Most of the companies we work with are totally unaware of what is available in terms of tapping the private markets and leveraging equity crowdfunding. The market is slowly but surely catching up, and we believe inside of the next 12-18 months, we’ll be seeing a huge uptick of healthcare companies taking advantage of the various Regulations that came from the JOBS Act. Specifically, we believe Reg A+ will see exponential growth within healthcare/Medtech companies.

 

Q: What impact do you think RegA+ can have on Medtech companies?

A: It is already having a huge impact. Companies are starting to jump in. In the last six months, I’ve personally gotten involved in supporting five Medtech companies that collectively raised over $200M. And it is just beginning – we are at a turning point, and the markets have a huge appetite for impact investment opportunities. This is a perfect setup for CEOs and founders that are running Medtech startups that are building solutions that can save a life or reduce suffering.

 

Q: What advice would you give a young Medtech entrepreneur as they begin their journey in capital raising and building their company?

A: Do your homework and see if a Regulation A+ capital raise path makes sense for you. Surround yourself with talented people that are committed to your vision. Stay positive and be willing to adjust as you go. 

 

Join the all-in-one platform empowering private capital markets.

Free forever, KoreConX makes it easy for participants in private capital markets to manage their investment portfolios, raise capital, and meet global compliance standards along every step of the way.

Book a demo
Join the All-In-One Platform empowering private capital markets.

Free forever, KoreConX makes it easy for participants in private capital markets to manage their investment portfolios, raise capital, and meet global compliance standards along every step of the way.